For investors who missed its earlier boom, now is the time to look into Lifestance Health Group again, according to Morgan Stanley.
Lifestance is rated overweight at Morgan Stanley with a $10 price target, implying 32% upside over the next 12 months against Friday's close.
LFST YTD mountain Lifestance Health Group stock.
The company is the largest independent behavioral health player, according to the note, with 3% market share in a $35 billion total addressable market.
The analyst said its market share gives it a "long runway for growth" and represents an "attractive compounding story."
Persons:
Morgan Stanley, Craig Hettenbach, Friday's, clawing, Lifestance, Hettenbach, Michael Bloom
Organizations:
Lifestance Health Group, Lifestance, U.S